Genotypic characterization of hepatitis B virus among human immunodeficiency virus patients at a tertiary health care facility in North Central Nigeria

Haruna Isa Mohammed *, Alaku Sarah and Pennap Grace Rinnecit

Department of Microbiology, Nasarawa State University, P.M.B. 1022, Keffi, Nigeria.

Publication history: Received on 29 April 2020; revised on 22 May 2020; accepted on 24 May 2020

Abstract
Hepatitis B virus (HBV) remains a major global health problem, with approximately 257 million people chronically infected. HBV co-infection with human immunodeficiency (HIV) virus is a major public health problem especially in developing countries. In this study, the genotypes of HBV were determined among 400 consenting HIV patients accessing healthcare in Federal Medical Center, Keffi, Nigeria by Nested Multiplex PCR method. Blood samples were collected and screened for HBsAg using ACON kit (ACON Laboratories Inc, USA). HBV DNA from 18 positive samples were genotyped. Of these, 5.6% were of genotype B, 22.2% were of genotype F and 72.2% were not-typeable. This study reported the circulation of genotypes B and F in the study population with predominance of not-typable strains. To the best of our knowledge, this is the first report of genotype F in a Nigerian study.

Keywords: Hepatitis B; HIV; Genotype; PCR; Nigeria

1. Introduction
Hepatitis B virus (HBV) remains a major global health problem, with approximately 257 million people chronically infected [1]. HBV, HCV and HIV are blood borne viral infections that have been widely reported in Nigeria [2]. Viral hepatitis is now the seventh leading cause of death worldwide with a 63% mortality increase to 1.45 million from 1990 to 2013 [3]. HBV accounts for most viral hepatitis associated deaths [3]. It is endemic in Africa and Western Pacific, with about 6% chronic infections in adults [1]. In Nigeria, HBV is reported to be the most common cause of liver disease [4]. The prevalence of HBV infection in the general population in Nigeria ranges from 9% to 39% [5,6,7], and being above 8% considered hyperendemic [8]. Pennap et al. also reported HBsAg prevalence of 12.5% among HIV infected patients [6]. Co-infection with HIV and HBV has become an important factor of co-morbidity and mortality [9]. HBV is a prototype member of the Hepadnaviridea family and it is classified into 10 genotypes (A-J) with different geographical distributions, clinical features and responses to treatment [10]. There is a call by World Health Organization to eliminate HBV and HCV infections as a public Health problem by 2030 [11]. To achieve this, robust sequence data of HBV isolated from patients are necessary. However, there is paucity of HBV genotyping data in Nigeria. Similarly, the knowledge of the circulating genotypes is important for optimal treatment strategy especially in chronic patients. Thus, the aim of this study was to detect the HBV genotypes circulating in the study area from individuals accessing healthcare in Federal Medical Centre, Keffi, Nigeria.

2. Materials and methods

2.1. Study area and population
The study centre for this research was Federal Medical Center, located in Keffi Local Government Area of Nasarawa State, Nigeria.

*Corresponding author: Haruna Isa Mohammed

Copyright © 2020 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution License 4.0.
Keffi is approximately 68 km from Abuja, the Federal Capital Territory and 128 km from Lafia, the capital of Nasarawa State.

Keffi town is located geographically between latitude 8°3'N of the equator and longitude 7°05'E and situated on an altitude of 850m above sea level [12]. The study was conducted on 400 consenting HIV positive individuals accessing Antiretroviral Therapy (ART) in Federal Medical Centre, Keffi Nigeria.

The socio-demographic information of the participants was obtained by the use of a designed questionnaire. The study involved both male and female adult patients accessing ART in Federal Medical Centre. Such patients are mainly from Keffi and other surrounding Local Government Areas. Those within Keffi metropolis were categorized as urban while those outside Keffi metropolis and other surrounding local government areas were categorized as rural.

2.2. Sample size determination
The sample size for this study was determined using the formula by Thrusfield [13]:

\[ N = \frac{(1.96)^2 \times P_{\text{exp}} (1 - P_{\text{exp}})}{D^2} \]

Where:

- \( N \) = Number of samples
- \( P_{\text{exp}} \) = Expected prevalence of 12.3
- \( D^2 \) = Desired absoluted precursor of 5

\[ N = 3.84 \times 0.12 \times 0.88 / (0.05)^2 \]

\[ N = 0.4048 / 0.0025 \]

\[ N = 161.92 \]

This was however rounded up to 400 samples.

2.3. Sample collection
A total of 400 blood samples were collected from patients in the ART clinic of Federal Medical Center, Keffi from May through August, 2018. About 2 ml of blood sample was collected from each consenting participant using a sterile vacutainer. The arm of the individual was tied with a tourniquet and the position of a vein was disinfected using cotton wool soaked in methylated spirit. Using a sterile labeled vacutainer for each participant, a blood sample was collected from each of them as described by Cheesbrough [14].

2.4. Laboratory analysis

2.4.1. Screening for HBsAg
Screening for HBsAg from the HIV infected patients’ blood samples was done using the Acon rapid test kit (ACON USA) in accordance with the manufacturer’s instructions.

2.4.2. Hepatitis B virus DNA extraction
The viral DNA was extracted using ZR Viral DNA Kit (Zymo Research Corp) according to the manufacturer’s instructions.

2.4.3. Buffer preparation
Before starting, beta mercaptoethanol (C₆H₁₂O₄S) was added to the Viral DNA buffer to a final dilution of 0.5% v/v. About 2 ml of 100% ethanol was also added to the 6 ml Viral Wash Buffer.
2.4.4 Procedure

Four hundred microliter of Genomic Lysis Buffer was added to 100 µl of the sample in a ratio 4:1. It was mixed by vortexing for 6 sec, and left to stand for 15 min at room temperature. The mixture was transferred to a Zymo-Spin IIC Column in a collection tube and centrifuged at 10,000 x g for 1 min. The flow through was discarded with the collection tube. The Zymo-Spin IIC Column was transferred to a new tube, and was then centrifuged at 10,000 x g for another 1 min. To the column, 200 µl DNA Pre-Wash Buffer was added and centrifuged at 10,000 x g for 1 min. Five hundred microlitre of g-DNA Wash Buffer was added to the spin column, centrifuged at 10,000 x g for 1 min and transferred to a clean micro centrifuge tube. Fifty microliter DNA Elution Buffer was added to the spin column incubated for 5 min at room temperature and then centrifuged at top speed for 30 sec to elude the DNA.

2.4.5 Oligonucleotide primers

The primer pairs used for this research work were adopted from the work of Hideo et al [15].

2.4.6 Polymerase chain reaction (PCR)

For PCR amplification, 15 µl of Master Mix containing tags, primers, nucleotide sequence, magnesium chloride, buffer, dNTP and template was added to 18 labeled PCR tubes because 18 of the HBsAg seropositive samples were picked at random for the first amplification (Nested PCR method). 0.48 µl each of the forward and reverse primers (P1) were added to the labeled PCR tubes and 9.2 µl of nuclease free water was also added.

A quantity of 1 µl of the extracted DNA added to the solution and centrifuged at 5000 rpm for 30 sec to bring down any hanging fluid by the side or cover of the PCR tubes. Finally, the PCR tubes containing the master mix, reverse and forward primers (P1), nuclease free water and extracted DNA was laid over the reaction mixture. The reaction was programmed to first incubate the mixture for 10 min at 95°C, followed by 40 cycles consisting of 94°C for 20 sec, 55°C for 20 sec, and 72°C for 1 min. Second round PCR (Nested-Multiplex PCR method) were performed for all the samples, with the common universal sense primer and mix A for types A through C and the common universal antisense primer and mix B for types D through F. A 1 ml aliquot of the first PCR product was added to tubes containing primers specific for types A through C and primers specific for types E through F. These were amplified for 40 cycles with the following parameters: preheated at 95°C for 10 min, 20 cycles of amplification at 94°C for 20 sec, 58°C for 20 sec, and 72°C for 30 sec.

2.4.7 Agarose gel electrophoresis

Agarose gel was prepared by mixing 1 g of Agarose powder with 100 ml 1X Tris Borate Ethylenediamine tetraacetic acid (EDTA) in a conical flask and dissolved by heating in a microwave oven for 10 min. The preparation was allowed to cool to about 450°C. The gel was poured into the tank with the gel casting trays and combs in place, 5 µl of Ethidium Bromide solution was added into the conical flask and gently swirled. The combs were carefully removed from the tank after gelling.

The first well was loaded with 5 µl of the XbP DNA Ladder and the second loaded with 10 µl nuclease free water mixed with 5 µl 6X loading dye. The remaining wells were loaded with 10 µl PCR amplicons of the second amplification. The voltage for the electrophoresis was set at 120 V and allowed to run for 45 min. The gel tray was removed and transferred to the computer room for observation and photographing of the results which were printed out.

2.5 Ethical approval

Ethical clearance and approval to conduct this study was sought and obtained from the Health Research Ethics Committee of Federal Medical Centre, Keffi, Nasarawa State on 6th February, 2018.

2.6 Statistical analysis

Chi Square analysis was used to test for significance using Smith Statistical Package (SSP) version 2.8. The statistical significance was determined at 5% probability (P≤0.05).
Table 1: The distribution of HBV genotypes in relation to socio-demographic factors among HIV positive patients accessing healthcare in Federal Medical Centre, Keffi, Nigeria.

<table>
<thead>
<tr>
<th>Socio-demographic</th>
<th>No. Examined</th>
<th>Genotype B (%)</th>
<th>Genotype F (%)</th>
<th>Not-typeable (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gender</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>7</td>
<td>1 (14.3)</td>
<td>0 (0.0)</td>
<td>6 (85.7)</td>
</tr>
<tr>
<td>Female</td>
<td>11</td>
<td>0 (0.0)</td>
<td>4 (36.3)</td>
<td>7 (63.6)</td>
</tr>
<tr>
<td>Total</td>
<td>18</td>
<td>1 (5.6)</td>
<td>4 (22.2)</td>
<td>13 (72.2)</td>
</tr>
<tr>
<td><strong>Age (Years)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18-27</td>
<td>1</td>
<td>0 (0.0)</td>
<td>1 (100.0)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>28-37</td>
<td>6</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
<td>6 (100.0)</td>
</tr>
<tr>
<td>38-47</td>
<td>8</td>
<td>1 (12.5)</td>
<td>2 (25.0)</td>
<td>5 (62.5)</td>
</tr>
<tr>
<td>48-57</td>
<td>2</td>
<td>0 (0.0)</td>
<td>1 (50.0)</td>
<td>1 (50.0)</td>
</tr>
<tr>
<td>≥58</td>
<td>1</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
<td>1 (100.0)</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>18</td>
<td>1 (5.6)</td>
<td>4 (22.2)</td>
<td>13 (72.2)</td>
</tr>
<tr>
<td><strong>Marital Status</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single</td>
<td>10</td>
<td>0 (0.0)</td>
<td>3 (30.0)</td>
<td>7 (70.0)</td>
</tr>
<tr>
<td>Married</td>
<td>6</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
<td>6 (100.0)</td>
</tr>
<tr>
<td>Divorced</td>
<td>2</td>
<td>1 (50.0)</td>
<td>1 (50.0)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>18</td>
<td>1 (5.6)</td>
<td>4 (22.2)</td>
<td>13 (72.2)</td>
</tr>
<tr>
<td><strong>Educational Status</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primary</td>
<td>2</td>
<td>0 (0.0)</td>
<td>2 (100.0)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>Secondary</td>
<td>10</td>
<td>0 (0.0)</td>
<td>2 (20.0)</td>
<td>8 (80.0)</td>
</tr>
<tr>
<td>Tertiary</td>
<td>6</td>
<td>1 (16.7)</td>
<td>0 (0.0)</td>
<td>5 (83.3)</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>18</td>
<td>1 (5.6)</td>
<td>4 (22.2)</td>
<td>13 (72.2)</td>
</tr>
<tr>
<td><strong>Occupation</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Student</td>
<td>10</td>
<td>0 (0.0)</td>
<td>2 (20.0)</td>
<td>8 (80.0)</td>
</tr>
<tr>
<td>Farmers</td>
<td>2</td>
<td>0 (0.0)</td>
<td>1 (50.0)</td>
<td>1 (50.0)</td>
</tr>
<tr>
<td>Unemployed</td>
<td>4</td>
<td>0 (0.0)</td>
<td>1 (25.0)</td>
<td>3 (75.0)</td>
</tr>
<tr>
<td>Artisan</td>
<td>1</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
<td>1 (100.0)</td>
</tr>
<tr>
<td>Civil Servant</td>
<td>1</td>
<td>1 (100.0)</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>18</td>
<td>1 (5.6)</td>
<td>4 (22.2)</td>
<td>13 (72.2)</td>
</tr>
<tr>
<td><strong>Locality</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urban</td>
<td>5</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
<td>5 (100.0)</td>
</tr>
<tr>
<td>Rural</td>
<td>13</td>
<td>1 (7.7)</td>
<td>4 (30.8)</td>
<td>8 (61.5)</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>18</td>
<td>1 (5.6)</td>
<td>4 (22.2)</td>
<td>13 (72.2)</td>
</tr>
</tbody>
</table>
3. Results and discussion

A total of 400 HIV seropositive patients participated in the study. Eighteen HBsAg positive samples were genotyped of which genotype B, F and genotypes that were not-typeable were observed (Figure 1). There were 7 males and 11 females. Of the 11 from females, four were of genotype F between the ages of 20-29 years and 40-49 years, three were married and one was divorced, two had a primary education and two, a tertiary education, two of them were students, one a farmer and one was unemployed. All of them came from the rural setting (Table 1). The B genotype was from a male, between the ages of 40-49 years, he was divorced, had a tertiary education, and an artisan from the rural setting. Of the not-typeable, 6 were males and seven were females. Their ages ranged from 29≥50 years. Singles were 7 and 6 were married. Those with a secondary education were 8 and 5 had a tertiary education. Students were 8, one was a farmer, one unemployed and one a civil servant. All of them were from the rural setting.

Hepatitis B virus infection among seropositive Human Immunodeficiency virus patients is a growing public health problem [6]. Four hundred HIV positive patients accessing ART in Federal Medical Centre, Keffi were recruited for this study.

Of the 18 HBV DNA genotyped, 22.2% were of genotype F, 5.6% of B while 72.2% were not-typeable (Figure 1). It is possible that HBV positive samples whose genotypes were not-typeable were from those whose primers were not available, errors in DNA extraction or PCR procedures. Earlier studies in Nigeria have reported the circulation of genotype E in Benin among HIV population [16]. Zampino et al. and Pennap et al. reported the HBV genotype E as the most frequent genotype in Nigeria [17, 18]. Genotype A has also been reported [19]. Genotype E was also reported among patients attending Akure hospitals in Nigeria [20]. Genotypes A and E were also found to be in Zaria with a predominance of E [21]. Another study done on occult hepatitis B virus among blood donors in Nigeria showed genotype E [22]. There is no published report of genotype F so far, it is possible that this genotype was acquired by those who travel to a country reported to have genotype F.

4. Conclusion

There was a HBV prevalence of 7.5% among HIV patients accessing healthcare in Federal Medical Centre, Keffi. Genotypes B (5.6%) and F (22.2%) were found to be in circulation in the study population, there was predominance (72.2%) of not-typeable genotypes. This study is reporting the novel appearance of genotype F in Nigeria. There is therefore a need to screen for HBV among HIV positive patients and also genotypes to increase treatment efficiency.
Compliance with ethical standards

Acknowledgments
The study team would like to thank the study participants who voluntarily participated in the study. However, this research did not receive any form of grant from governmental or non-governmental organizations.

Disclosure of conflict of interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Statement of ethical approval
Ethical clearance and approval to conduct this study was sought and obtained from the Health Research Ethics Committee of Federal Medical Centre, Keffi, Nasarawa State on 6th February, 2018.

Statement of informed consent
All individuals included in this study completed and signed an informed consent form. Individual anonymity was treated with confidentiality and for the purpose of this study.

References


How to cite this article